首页> 外文期刊>Scientific reports. >Down-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of urothelial carcinoma cell lines via the NF-κB pathway
【24h】

Down-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of urothelial carcinoma cell lines via the NF-κB pathway

机译:ShRNA构建体的HMGB1表达的下调抑制了通过NF-κB途径的尿系系癌细胞系的生物活性

获取原文
           

摘要

The high mobility group box 1 (HMGB1), which is a highly conserved and evolutionarily non-histone nuclear protein, has been shown to associate with a variety of biological important processes, such as transcription, DNA repair, differentiation, and extracellular signalling. High HMGB1 expression has been reported in many cancers, such as prostate, kidney, ovarian, and gastric cancer. However, there have been few studies of the function of HMGB1 in the malignant biological behaviour of bladder urothelial carcinoma (BUC), and the potential mechanism of HMGB1 in the pathogenesis of BUC remains unclear. Thus, in this study, we constructed plasmid vectors that are capable of synthesizing specific shRNAs targeting HMGB1 and transfected them into BUC cells to persistently suppress the endogenous gene expression of HMGB1. The expression of HMGB1, the bioactivity of BUC cells, including proliferation, apoptosis, cell cycle distribution, migration and invasion, and the effects of HMGB1 knockdown on downstream signalling pathways were investigated. Our data suggest that HMGB1 promotes the malignant biological behaviour of BUC, and that this effect may be partially mediated by the NF-κB signalling pathway. HMGB1 may serve as a potential therapeutic target for BUC in the future.
机译:已经显示出高度保守和进化的非组蛋白核蛋白的高迁移率组盒1(HMGB1),其与各种生物重要的方法相关联,例如转录,DNA修复,分化和细胞外信号传导。在许多癌症中报道了高HMGB1表达,例如前列腺,肾,卵巢和胃癌。然而,迄今为止患有HMGB1在膀胱尿路上皮癌(BUC)的恶性生物学行为中的功能,以及HMGB1在BUC发病机制中的潜在机制尚不清楚。因此,在本研究中,我们构建了能够合成靶向HMGB1的特异性SHRNA的质粒载体,并将其转染到BUC细胞中以持续抑制HMGB1的内源基因表达。研究了HMGB1,Buc细胞的生物活性,包括增殖,凋亡,细胞周期分布,迁移和侵袭以及HMGB1敲低对下游信号传导途径的影响。我们的数据表明,HMGB1促进了Buc的恶性生物学行为,并且这种效果可以部分地由NF-κB信号通路介导。 HMGB1可作为未来为BUC的潜在治疗目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号